Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

Completed · Phase 1

Conditions studied: Scleroderma, Interstitial Lung Disease

In brief

This study evaluates if dabigatran etexilate is safe for use in patients with Scleroderma and Interstitial Lung Disease. All patients will receive 75mg of dabigatran etexilate twice a day for 6 months.

Key facts

Study ID

NCT02426229

Run by

Medical University of South Carolina

People needed

15

Starts

2016-02-01

Expected to finish

2018-06-21

Last updated by the study team

2018-07-13

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 and ≤ 70 years
• All patients must fulfill the ACR/EULAR criteria for SSc. Patients may have limited (cutaneous thickening distal, but not proximal to elbows and knees, with or without facial involvement) or diffuse (cutaneous thickening proximal to elbows and knees, often involving the chest or abdomen) cutaneous SSc, or systemic sclerosis sine scleroderma
• SSc for less than 7 years, with onset defined as the date of the first non-Raynaud phenomenon manifestation.
• All patients must have interstitial lung disease defined by any ground glass on HRCT and >20% involvement of HRCT by pulmonary fibrosis and/or FVC <70% predicted

You may not qualify if…

• Inability to sign consent
• Currently enrolled in another clinical trial
• FVC < 40% predicted and/or DLCO (corrected for hemoglobin) < 30% of predicted (suggesting severe probably irreparable disease)
• Other serious concomitant medical illnesses (e.g., cancer) limiting life expectancy to <1 year at time of enrollment
• FEV1/FVC ratio < 65% (suggesting obstructive disease)
• Clinically significant pulmonary hypertension requiring treatment, based on the clinician's judgment.
• Smoking of cigars, pipes or cigarettes within 3 months prior to and during enrollment
• Clinically significant abnormalities on chest x-ray other than interstitial lung disease (e.g., lung mass, evidence of active pulmonary infection, emphysema)
• Use of prednisone (or equivalent) in doses > 10 mg daily within 3 months prior to and during enrollment
• Use of colchicine, D-penicillamine, cyclophosphamide, mycophenolate mofetil, azathioprine, endothelin receptor antagonists, phosphodiesterase type-5 inhibitors, prostanoids, tyrosine kinase inhibitors, sirolimus, rituximab, perfinidone or other "disease modifying medications" within 3 months prior to and during enrollment
• Pregnancy or lack of use of birth control method in women of childbearing age or lactating
• Liver disease or increased baseline liver enzyme levels (ALT >3 x upper limit of normal)
• Use of CYP450 inhibitors/inducers
• Hemoglobin < 10g/L
• If of child bearing potential, unwillingness to employ a reliable means of contraception (condom, abstinence, IUD, tubal ligation, vasectomy)
• Active infection
• Creatinine clearance <30 ml/min
• Post transplantation
• Active medical and psychiatric conditions which the investigator may consider would interfere with the subject's treatment, assessment, or compliance with the protocol
• Anticoagulation-related exclusions include:
• Current anticoagulation therapy with warfarin
• Increased risk of bleeding (e.g., uncorrectable inherited or acquired bleeding disorder)
• Platelet count <100,000/cmm or hematocrit <30% or > 55%
• History of severe gastrointestinal bleeding within 6 months of screening
• Known gastric antral vascular ectasia (GAVE) or gastric/intestinal arterial-venous malformations (AVMs)

Where it is running

• Medical University of South Carolina — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.